Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old

Each year, around 300,000 Herpes Zoster (HZ) cases are observed in the German population, resulting in costs over €182 million to society. The objective of this study was to estimate the potential public health and economic impact of the new Adjuvanted Recombinant Zoster Vaccine (RZV, Shingrix) in t...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Hum Vaccin Immunother
Hlavní autoři: Van Oorschot, Desirée, Anastassopoulou, Anastassia, Poulsen Nautrup, Barbara, Varghese, Lijoy, von Krempelhuber, Alfred, Neine, Mohamed, Lorenc, Stéphane, Curran, Desmond
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2018
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6363061/
https://ncbi.nlm.nih.gov/pubmed/30130448
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2018.1509645
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky